Last reviewed · How we verify
NCT04449393
Enamel Matrix Derivative in Non-surgical Periodontal Treatment
NA trial testing Emdogain® FL in Periodontitis in 22 participants. Completed in 1 July 2022.
1 May 2022
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 15 September 2020 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Emdogain® FL
- Scaling and root planing
Conditions studied
- Periodontitis — all drugs for Periodontitis →
Sponsor
Medical University of Vienna
Who can join
Adults 25 to 75, any sex, with Periodontitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to investigate the effect of enamel matrix derivative in addition to scaling and root planing in comparison to scaling and root planing only in periodontitis patients that have already undergone initial periodontal therapy and are in periodontal maintenance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of enamel matrix derivative in nonsurgical periodontal therapy on pro-inflammatory profiles, microbial environment and clinical outcome: a randomized clinical trial.
Wehner C, Tur D, Durstberger G, Laky M, et al · · 2023 · cited 6× · PMID 37843637 · DOI 10.1007/s00784-023-05254-1
Verify or expand the search:
- PubMed search for NCT04449393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Periodontitis
Currently open trials in the same condition.
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07535177 — Gas6 and Soluble MerTK in Periodontal Diseases · recruiting
- NCT07491848 — Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D · recruiting
- NCT07421960 — Investigation of the Relationship Between Periodontitis and Sleep Quality · recruiting
- NCT07532694 — Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients · NA · recruiting
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04449393 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 25 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04449393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing